IMR is a company with interests and activities focused on innovations in the field of personalized medicine and biotechnology. Personalized medicine service is focused on modeling, developing, and managing logistics projects and patient support programmes related to companion diagnostics. This involves combining innovative diagnostic technologies with pathological expertise to assess the genetic and molecular characteristics of the tumor in various oncological diseases. The company develops and provides a fully completed diagnostic process to assess the tumor’s molecular (mutation and protein expression) status, including providing the appropriate reagents for each type of diagnosis. In performing patient support programmes a holistic working model is applied – connecting key participants in the healthcare field: patients, diagnosticians, medical specialists, and pharma industry representatives.
Area of expertise
- EGFR companion diagnostics for patients diagnosed with non-small cell lung cancer (NSCLC)
- PD-L1 patient support programmes for patients with non-small cell lung cancer and urothelial carcinoma
- RAS (KRAS, NRAS) companion diagnostics for patients diagnosed with colorectal cancer